Metraipolis › archive › dc_eb5c262820ee
Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41007743
- DOI
- 10.3390/biomedicines13092180
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T02:29:19.551Z
- SHA-256 of the archived text
36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502- Stable URL of this page
https://metraipolis.com/documento/dc_eb5c262820ee
How to cite
Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743 — Europe PMC (en), https://europepmc.org/article/MED/41007743 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb5c262820ee (Metraipolis archive dc_eb5c262820ee, sha256 36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502)
BibTeX
@misc{dceb5c262820ee,
title = {Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular-Respiratory Pharmacology, and… — Europe PMC PMID:41007743},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41007743},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb5c262820ee; sha256 36904bd704d591b3943938591319b5be97a10e5c167a84e879ccb3860e29e502},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41007743. Agents can read the archived copy with the MCP tool read_document.